株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ドライアイ(DED)- 市場洞察、疫学、市場予測 2028年

Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 602051
出版日 ページ情報 英文 156 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
ドライアイ(DED)- 市場洞察、疫学、市場予測 2028年 Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年08月01日 ページ情報: 英文 156 Pages
概要

世界の主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のドライアイ有病者数は2017年に1,193万9,169人、欧州5カ国のドライアイ市場は6億262万米ドルと推計されています。

欧州5カ国(英国、ドイツ、フランス、イタリア、スペイン)のドライアイ市場を調査し、市場の概要、疾病の疫学、有病数の推移と予測、上市済み治療薬および新薬の概要、国別の市場規模の推移と予測、アンメットニーズ、市場の成長要因および障壁などについてまとめています。

目次

第1章 重要洞察

第2章 ドライアイ疾患市場の概要

  • 市場シェア(実数値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • ドライアイの歴史的概要
  • ドライアイ疾患の分類スキーム
  • 病因と危険因子
  • 原因
  • 兆候と症状
  • ドライアイ病の病理
  • 診断

第4章 欧州5カ国の疫学と患者数

  • 主な調査結果
  • キーオピニオンリーダーの見解:疫学
  • 欧州5ヶ国ドライアイの総有病数

第5章 ドライアイの疫学:国別

  • 欧州5カ国
    • 仮定と根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第6章 ドライアイの治療と管理

第7章 アンメットニーズ

第8章 上市済み治療薬

  • アイケルビス:参天製薬
    • 製品説明
    • 規制のマイルストーン
    • 安全性と有効性
    • 製品プロファイル

第9章 新薬

  • Visomitin:Mitotech pharma
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 長所と短所
    • 製品プロファイル
  • RGN-259:ReGen Tree
  • HL036:HanAll BioPharma
  • Tavilermide ophthalmic solution:Mimetogen Pharmaceuticals
  • OCU310:Ocugen
  • KPI-121:Kala Pharmaceuticals
  • CyclASol:Novaliq
  • CEQUA:Sun Pharma
  • Tivanisiran:Sylentis SA
  • Reproxalap:Aldeyra Therapeutics
  • Xiidra:Novartis

第10章 欧州5カ国のドライアイ市場の分析

  • 主な調査結果
  • キーオピニオンリーダーの見解:治療と診断
  • 欧州5カ国の市場規模
  • 市場規模:治療薬別
  • 市場規模:種類別

第11章 市場概要:国別

  • 欧州5カ国:市場の見通し
  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
    • 市場規模:タイプ別
  • フランス
  • イタリア
  • スペイン
  • 英国

第12章 市場の成長要因

第13章 市場の障壁

章14 付録

  • 調査方法

第15章 DelveInsightのサービス内容

第16章 免責事項

第17章 DelveInsightについて

図表

List of Tables

  • Table 1 Prevalent Population of Dry Eye Disease in the 7MM (2017-2028)
  • Table 2 Total Adult Cases of Dry Eye Disease in the 7MM (2017-2028)
  • Table 3 Age-specific Prevalent Cases of Dry Eye Disease in the United States (2017-2028)
  • Table 4 Prevalence of DED in Adults in the United States (2017-2028)
  • Table 5 Gender-specific Prevalence of Dry Eye Disease in the United States (2017-2028)
  • Table 6 Severity-specific Prevalent Cases of Dry Eye Disease in the United States (2017-2028)
  • Table 7 Prevalence of Clinical Manifestation of DED in Adults in the United States (2017-2028)
  • Table 8 Diagnosed Cases of Dry Eye Disease in the United States (2017-2028)
  • Table 9 Prevalence of Dry Eye Disease in Germany by Age-group (2017-2028)
  • Table 10 Total Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
  • Table 11 Gender-specific Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
  • Table 12 Severity-specific prevalent cases of Dry Eye Disease in Germany (2017-2028)
  • Table 13 Prevalence of Clinical Manifestation of DED in Adults in Germany (2017-2028)
  • Table 14 Diagnosed Cases of Dry Eye Disease in Germany (2017-2028)
  • Table 15 Age-specific Prevalence of Dry Eye Disease in France (2017-2028)
  • Table 16 Total Prevalence of Dry Eye Disease in France (2017-2028)
  • Table 17 Gender-specific Prevalent Cases of Dry Eye Disease in France (2017-2028)
  • Table 18 Severity Specific Prevalence of Dry Eye Disease in France (2017-2028)
  • Table 19 Prevalence of Clinical Manifestation of DED in Adults in France (2017-2028)
  • Table 20 Diagnosed Cases of Dry Eye Disease in France (2017-2028)
  • Table 21 Prevalent Cases of Dry Eye Disease By Age-group in Italy (2017-2028)
  • Table 22 Total Prevalence of Dry Eye Disease in Adults in Italy (2017-2028)
  • Table 23 Gender-specific Prevalence of Dry Eye Disease in Italy (2017-2028)
  • Table 24 Severity-specific Prevalent Cases of Dry Eye Disease in Italy (2017-2028)
  • Table 25 Prevalence of Clinical Manifestation of DED in Adults in Italy (2017-2028)
  • Table 26 Diagnosed Cases of Dry Eye Disease in Italy (2017-2028)
  • Table 27 Prevalent Cases of Dry Eye Disease by Age-group in Spain (2017-2028)
  • Table 28 Total Prevalence of Dry Eye Disease in Adults in Spain (2017-2028)
  • Table 29 Gender-specific Prevalence of Dry Eye Disease in Spain (2017-2028)
  • Table 30 Severity-specific Prevalent Cases of Dry Eye Disease in Spain (2017-2028)
  • Table 31 Prevalence of Clinical Manifestation of DED in Adults in Spain (2017-2028)
  • Table 32 Diagnosed Cases of Dry Eye Disease in Spain (2017-2028)
  • Table 33 Prevalent Cases of Dry Eye Disease by Age-group in the United Kingdom (2017-2028)
  • Table 34 Total Prevalence of Dry Eye Disease in Adults the United Kingdom (2017-2028)
  • Table 35 Gender-specific Prevalence of DED in the United Kingdom (2017-2028)
  • Table 36 Severity-specific Prevalent Cases of Dry Eye Disease in the UK (2017-2028)
  • Table 37 Prevalence of Clinical Manifestation of DED in Adults in the UK (2017-2028)
  • Table 38 Diagnosed Cases of Dry Eye Disease in the United Kingdom(2017-2028)
  • Table 39 Age-Group Specific Prevalence of Dry Eye Disease in Japan (2017-2028)
  • Table 40 Total Prevalence of Dry Eye Disease in Adults Japan (2017-2028)
  • Table 41 Gender-specific Prevalence of Dry Eye Disease in Japan (2017-2028)
  • Table 42 Severity-specific Prevalent Cases of Dry Eye Disease in Japan (2017-2028)
  • Table 43 Prevalence of Clinical Manifestation of DED in Adults in Japan (2017-2028)
  • Table 44 Diagnosed Cases of Dry Eye Disease in Japan (2017-2028)
  • Table 45 Provigil, Clinical Trial Description, 2019
  • Table 46 Solriamfetol, Clinical Trial Description, 2019
  • Table 47 Key cross competition- Emerging Therapies
  • Table 48 7 Major Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 49 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 50 United States Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 51 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 52 Germany Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 53 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 54 France Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 55 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 56 Italy Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 57 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 58 Spain Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 59 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 60 United Kingdom Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 61 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 62 Japan Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Table 63 Therapy-Based Market Size of Dry Eye Disease in USD Million (2017-2028)

List of Figures

  • Figure 1 Airway obstruction in Sleep Apnea
  • Figure 2 Apnea / hypopnea cycle
  • Figure 3 Pathological relationship between sleep apnea and cardiovascular disease
  • Figure 4 Risk Factors for Dry Eye Disease
  • Figure 5 Clinical algorithm for implementation of clinical practice guidelines.
  • Figure 6 Prevalent Population of Dry Eye Disease in the 7MM (2017-2028)
  • Figure 7 Total Adult DED Cases in 7MM (2017-2028)
  • Figure 8 Prevalence of Dry Eye Disease by Age Group in the United States (2017-2028)
  • Figure 9 Prevalence of DED in Adults in the United States (2017-2028)
  • Figure 10 Gender Specific Prevalence of Dry Eye Disease in the United States (2017-2028)
  • Figure 11 Severity-specific Prevalent Cases of Dry Eye Disease in the US (2017-2028)
  • Figure 12 Prevalence of Clinical Manifestation of DED in Adults in the United States (2017-2028)
  • Figure 13 Diagnosed Cases of Dry Eye Disease in the United States (2017-2028)
  • Figure 14 Prevalence of Dry Eye Disease in Germany by Age Group (2017-2028)
  • Figure 15 Total Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
  • Figure 16 Gender Specific Prevalence of Dry Eye Disease in Adults in Germany (2017-2028)
  • Figure 17 Severity specific prevalent cases of Dry Eye Disease in Germany (2017-2028)
  • Figure 18 Prevalence of Clinical Manifestation of DED in Adults in Germany (2017-2028)
  • Figure 19 Diagnosed Cases of Dry Eye Disease in Germany (2017-2028)
  • Figure 20 Prevalence of Dry Eye Disease in France by Age Group (2017-2028)
  • Figure 21 Total Prevalence of Dry Eye Disease in Adults in France (2017-2028)
  • Figure 22 Gender-specific Prevalent Cases of Dry Eye Disease in France (2017-2028)
  • Figure 23 Severity Specific Prevalence of Dry Eye Disease in France (2017-2028)
  • Figure 24 Prevalence of Clinical Manifestation of DED in Adults in France (2017-2028)
  • Figure 25 Diagnosed Cases of Dry Eye Disease in France (2017-2028)
  • Figure 26 Prevalent Cases of Dry Eye Disease By Age Group in Italy (2017-2028)
  • Figure 27 Total Prevalence of Dry Eye Disease in Adults in Italy (2017-2028)
  • Figure 28 Gender-specific Prevalence of Dry Eye Disease in Italy (2017-2028)
  • Figure 29 Severity specific Prevalent Cases of Dry Eye Disease in Italy (2017-2028)
  • Figure 30 Prevalence of Clinical Manifestation of DED in Adults in Italy (2017-2028)
  • Figure 31 Diagnosed Cases of Dry Eye Disease in Italy (2017-2028)
  • Figure 32 Prevalence of Dry Eye Disease by Age Group in Spain (2017-2028)
  • Figure 33 Total Prevalence of Dry Eye Disease in Adults in Spain (2017-2028)
  • Figure 34 Gender Specific Prevalence of Dry Eye Disease in Spain (2017-2028)
  • Figure 35 Severity specific Prevalent Cases of Dry Eye Disease in Spain (2017-2028)
  • Figure 36 Prevalence of Clinical Manifestation of DED in Adults in Spain (2017-2028)
  • Figure 37 Diagnosed Cases of Dry Eye Disease in Spain (2017-2028)
  • Figure 38 Prevalent Cases of Dry Eye Disease in the United Kingdom (2017-2028)
  • Figure 39 Total Prevalence of Dry Eye Disease in Adults the United Kingdom (2017-2028)
  • Figure 40 Gender Specific Prevalence of DED in the United Kingdom (2017-2028)
  • Figure 41 Severity specific Prevalent Cases of Dry Eye Disease in the UK (2017-2028)
  • Figure 42 Prevalence of Clinical Manifestation of DED in Adults in the UK (2017-2028)
  • Figure 43 Diagnosed Cases of Dry Eye Disease in the United Kingdom (2017-2028)
  • Figure 44 Age Group Specific Prevalence of Dry Eye Disease in Japan (2017-2028)
  • Figure 45 Total Prevalence of Dry Eye Disease in Adults Japan (2017-2028)
  • Figure 46 Gender Specific Prevalence of Dry Eye Disease in Japan (2017-2028)
  • Figure 47 Severity specific Prevalent Cases of Dry Eye Disease in Japan (2017-2028)
  • Figure 48 Prevalence of Clinical Manifestation of DED in Adults in Japan (2017-2028)
  • Figure 49 Diagnosed Cases of Dry Eye Disease in Japan (2017-2028)
  • Figure 50 Unmet Needs for Dry Eye Disease
  • Figure 51 7 Major Market Size of Dry Eye Disease in USD Million (2017-2028)
  • Figure 52 Therapy Based Market Size of DED in 7MM in USD Million (2017-2028)
  • Figure 53 Market Size of Dry Eye Disease in the United States, USD Millions (2017-2028)
  • Figure 54 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 55 Market Size of Dry Eye Disease in Germany, USD Millions (2017-2028)
  • Figure 56 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 57 Market Size of Dry Eye Disease in France USD Millions (2017-2028)
  • Figure 58 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 59 Market Size of Dry Eye Disease in Italy, USD Millions (2017-2028)
  • Figure 60 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 61 Market Size of Dry Eye Disease in Spain, USD Millions (2017-2028)
  • Figure 62 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 63 Market Size of Dry Eye Disease in the UK, USD Millions (2017-2028)
  • Figure 64 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 65 Market Size of Dry Eye Disease in the UK, USD Millions (2017-2028)
  • Figure 66 Therapy Based Market Size of DED in USD Million (2017-2028)
  • Figure 67 Market Drivers
  • Figure 68 Market Barriers
目次
Product Code: DIMI0274

DelveInsight's 'Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DED in EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dry Eye Disease (DED) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017-2028

Dry Eye Disease (DED) - Disease Understanding and Treatment Algorithm

The DelveInsight Dry Eye Disease (DED) market report gives the thorough understanding of the Dry Eye Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dry Eye Disease in Europe.

Dry Eye Disease Epidemiology

The Dry Eye Disease (DED) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 5 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed cases, gender-specific prevalent cases, severity-specific prevalent cases, type-specific prevalent cases and age-specific prevalent cases) scenario of Dry Eye Disease (DED) in the 7MM covering EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Dry Eye Disease (DED) in 7 MM was found to be 11,939,169, in the year 2017.

Dry Eye Disease Drug Chapters

This segment of the Dry Eye Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are many over the counter therapies such as "artificial tears", ocular surface lubricants that have been used since a very long time to treat DED. These therapies have been included in DelveInsight's forecast model since it focuses both on the prescription therapies as well as OTC products such as Hyaluronic acid, Polyvinyl alcohol, Sodium chloride, Hypromellose, Poly(1-vinyl-2-pyrrolidon), Povidone, Carboxymethylcellulose, Ketorolac tromethamine, Hypromellose and many others that are being used to treat DED. Some of the major products belonging to this category are Novatears/Evotears (Novaliq/Ursapharm), Genteal/Systane/Tears Naturale (Alcon/Novartis), Refresh/Optive (Allergan), Soothe (Bausch & Lomb/Valeant, Visu XL/Xailin Hydrate/Xailin Gel (Visufarma) and many others. Detailed chapter for upcoming therapies like Visomitin, RGN-259 and many others have been covered in the report.

Dry Eye Disease Market Outlook

The Dry Eye Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Dry Eye Disease in 5MM was found to be USD 602.62 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Dry Eye Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dry Eye Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dry Eye Disease Report Key Strengths

  • 10 Year Forecast
  • 5MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Dry Eye Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Dry Eye Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Dry Eye Disease market
  • To understand the future market competition in the Dry Eye Disease market.

Table of Contents

1. Key Insights

2. Dry Eye Disease Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Dry Eye Disease in 2017
  • 2.2. Market Share (%) Distribution of Dry Eye Disease in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Historical overview of dry eye
  • 3.3. Classification schemes for dry eye disease
  • 3.4. Etiology and risk factors
  • 3.5. Causes
  • 3.6. Signs and Symptoms
  • 3.7. Pathology of Dry Eye Disease
  • 3.8. Diagnosis

4. Epidemiology and Patient Population - EU5 Markets

  • 4.1. Key Findings
  • 4.2. KOL's Views: Epidemiology
  • 4.3. EU5 Total Prevalent Patient Population of Dry Eye Disease

5. Country Wise-Epidemiology of Dry Eye Disease

  • 5.1. EU5
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Germany
    • 5.1.3. France
    • 5.1.4. Italy
    • 5.1.5. Spain
    • 5.1.6. The United Kingdom

6. Treatment and Management of Dry Eye Disease

7. Unmet Needs

8. Marketed Drugs

  • 8.1. IKERVIS: Santen Pharmaceutical
    • 8.1.1. Product Description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Safety and Efficacy
    • 8.1.4. Product Profile

9. Emerging Therapies

  • 9.1. Visomitin: Mitotech pharma
    • 9.1.1. Product Description
    • 9.1.2. Other development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Advantages and Disadvantages
    • 9.1.6. Product Profile
  • 9.2. RGN-259: ReGen Tree
    • 9.2.1. Product Description
    • 9.2.2. Other development Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Advantages and Disadvantages
    • 9.2.6. Product Profile
  • 9.3. HL036: HanAll BioPharma
    • 9.3.1. Product Description
    • 9.3.2. Other development Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Advantages and Disadvantages
    • 9.3.6. Product Profile
  • 9.4. Tavilermide ophthalmic solution: Mimetogen Pharmaceuticals
    • 9.4.1. Product Description
    • 9.4.2. Other development Activities
    • 9.4.3. Clinical Development
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Advantages and Disadvantages
    • 9.4.6. Product Profile
  • 9.5. OCU310: Ocugen
    • 9.5.1. Product Description
    • 9.5.2. Other development Activities
    • 9.5.3. Clinical Development
    • 9.5.4. Safety and Efficacy
    • 9.5.5. Advantages and Disadvantages
    • 9.5.6. Product Profile
  • 9.6. KPI-121: Kala Pharmaceuticals
    • 9.6.1. Product Description
    • 9.6.2. Other development Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Safety and Efficacy
    • 9.6.5. Advantages and Disadvantages
    • 9.6.6. Product Profile
  • 9.7. CyclASol: Novaliq
    • 9.7.1. Product Description
    • 9.7.2. Other Development Activities
    • 9.7.3. Clinical Development
    • 9.7.4. Safety and Efficacy
    • 9.7.5. Advantages and Disadvantages
    • 9.7.6. Product Profile
  • 9.8. CEQUA: Sun Pharma
    • 9.8.1. Product Description
    • 9.8.2. Clinical Development
    • 9.8.3. Safety and Efficacy
    • 9.8.4. Advantages and Disadvantages
    • 9.8.5. Product Profile
  • 9.9. Tivanisiran: Sylentis, S.A.
    • 9.9.1. Product Description
    • 9.9.2. Other Development Activity
    • 9.9.3. Clinical Development
    • 9.9.4. Safety and Efficacy
    • 9.9.5. Advantages and Disadvantages
    • 9.9.6. Product Profile
  • 9.10. Reproxalap: Aldeyra Therapeutics
    • 9.10.1. Product Description
    • 9.10.2. Clinical Development
    • 9.10.3. Safety and Efficacy
    • 9.10.4. Advantages and Disadvantages
    • 9.10.5. Product Profile
  • 9.11. Xiidra: Novartis
    • 9.11.1. Product Description
    • 9.11.2. Other Development Activity
    • 9.11.3. Clinical Development
    • 9.11.4. Safety and Efficacy
    • 9.11.5. Advantages and Disadvantages
    • 9.11.6. Product Profile

10. Dry Eye Disease: EU-5 Market Analysis

  • 10.1. Key Findings
  • 10.2. KOL's Views: Treatment & Diagnosis
  • 10.3. Market Size of Dry Eye Disease in EU5
  • 10.4. Market Size of Dry Eye Disease by Therapies
  • 10.5. Market size of Dry Eye Disease by Types

11. Market Outlook by Country

  • 11.1. EU-5 Countries: Market Outlook
  • 11.2. Germany
    • 11.2.1. Total Market size of Dry Eye Disease
    • 11.2.2. Market Size of Dry Eye Disease by Therapies
    • 11.2.3. Total Market size of Dry Eye Disease by Types
  • 11.3. France
    • 11.3.1. Total Market size of Dry Eye Disease
    • 11.3.2. Market Size of Dry Eye Disease by Therapies
    • 11.3.3. Total Market size of Dry Eye Disease by Types
  • 11.4. Italy
    • 11.4.1. Total Market size of Dry Eye Disease
    • 11.4.2. Market Size of Dry Eye Disease by Therapies
    • 11.4.3. Total Market size of Dry Eye Disease by Types
  • 11.5. Spain
    • 11.5.1. Total Market size of Dry Eye Disease
    • 11.5.2. Market Size of Dry Eye Disease by Therapies
    • 11.5.3. Total Market size of Dry Eye Disease by Types
  • 11.6. United Kingdom
    • 11.6.1. Total Market size of Dry Eye Disease
    • 11.6.2. Market Size of Dry Eye Disease by Therapies
    • 11.6.3. Total Market size of Dry Eye Disease by Types

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Back to Top